Clinical trials: sponsored by Fox Chase Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003109
- Testing
- irinotecan hydrochloride, raltitrexed
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Fox Chase Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00021346
- Testing
- carboplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Fox Chase Cancer Center
Parapsoriasis
Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis
Parapsoriasis is a term that refers to a precursor stage of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides(MF). Complete responses (clearing) of early presentations of CTCL/MF have been shown to be associated with long-term…
- Trial name
- NCT00322296
- Testing
- Bexarotene 1% gel
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer
RATIONALE: A computer-based survey and communication aid may help physicians and patients to communicate better and help make treatment decisions easier.
- Trial name
- NCT00244868
- Testing
- counseling intervention, educational intervention
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Fox Chase Cancer Center
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
This phase I trial studies the side effects and best dose of cetuximab when given together with everolimus in treating patients with metastatic or recurrent colon cancer or head and neck cancer.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT01637194
- Testing
- everolimus, cetuximab, pharmacological study
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fox Chase Cancer Center
Uterine Cervical Neoplasms
Facilitating Follow-Up Adherence for Abnormal Pap Smears
Objective: Previous studies have suggested that psycho-educational interventions delivered by telephone improve adherence to initial colposcopy after an abnormal Pap smear.
- Trial name
- TC3 (NCT01561326)
- Testing
- Cognitive-affective barriers counseling, Cognitive-affective barriers counseling via brochure, standard care
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer, Breast Cancer
Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting
This study was designed to provide a preliminary evaluation of the efficacy and usability of the 2004 revised version of the booklet, Facing Forward , Life After Cancer Treatment, (hereafter,Facing Forward) published by the…
- Conditions
- Prostate Cancer, Breast Cancer, Colorectal Cancer, Thoracic Cancer
- Trial name
- NCT01440855
- Testing
- CIS (Cancer Information Service) Information Sheet, Facing Forward booklet
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Fox Chase Cancer Center
Carcinoma, Non-Small-Cell Lung
Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer
The purpose of this study is to determine the role of cetuximab (Erbitux) with chemotherapy for advanced colorectal carcinoma. This study will determine if this new agent can improve one's response to standard treatment.
- Trial name
- NCT00315185
- Testing
- Cetuximab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fox Chase Cancer Center
Lung Cancer
Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.
- Trial name
- NCT00039507
- Testing
- conventional surgery, radiofrequency ablation
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
A New Radiation Therapy Planning System in Patients Undergoing Radiation Therapy for Cancer
RATIONALE: A new radiation therapy planning system may help doctors plan better treatment for patients with cancer. PURPOSE: This clinical trial is studying a new radiation therapy planning system in patients undergoing radiation…
- Trial name
- NCT00436397
- Testing
- radiation therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer
Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer
RATIONALE: New imaging procedures such as CT-on-rails™ may improve the ability to pinpoint the location of the tumor and decrease radiation therapy damage to healthy tissue.
- Trial name
- NCT00084526
- Testing
- computed tomography, ultrasound imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fox Chase Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Computed Tomography in Detecting Movement of the Esophagus in Patients Undergoing Radiation Therapy to the Chest
RATIONALE: Comparing results of diagnostic procedures, such as computed tomography scan (CT scan), done before and after radiation therapy to help detect movement of the esophagus may help doctors plan the best treatment.
- Trial name
- NCT00433524
- Testing
- computed tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fox Chase Cancer Center
Colorectal Cancer
Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in standard radiation therapy) with incorporated boost (an…
- Trial name
- NCT00084591
- Testing
- capecitabine, conventional surgery, neoadjuvant therapy
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Breast Cancer, Depression
Physical Activity or Usual Care in Preventing Weight Gain in Women With Stage I or Stage II Breast Cancer Undergoing Chemotherapy
RATIONALE: Physical activity may prevent or reduce weight gain in women receiving chemotherapy for early stage breast cancer. PURPOSE: This randomized phase I/II trial is studying physical activity to see how well it works…
- Conditions
- Breast Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00509626
- Testing
- exercise intervention, questionnaire administration, CAM exercise therapy
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- Fox Chase Cancer Center
Lung Cancer
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00062322
- Testing
- cisplatin, irinotecan hydrochloride, conventional surgery
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084513
- Testing
- trastuzumab, imatinib mesylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fox Chase Cancer Center